Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 154 results for multiple sclerosis

  1. QTUG for assessing falls risk and frailty (MIB73)

    NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)

    Medtech innovation briefing
    Published
    26 July 2016

  2. Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)

    This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.

    NICE guideline
    Published
    15 October 2025

    Sections for NG252

  3. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued Reference number: GID-TAG337

    Technology appraisal guidance
    Discontinued

  4. Self-expanding implant insertion into the intersphincteric space for faecal incontinence (HTG564)

    Evidence-based recommendations on self-expanding implant insertion into the intersphincteric space for faecal incontinence. This involves inserting implants that expand and press together, forming a ring that creates an artificial sphincter.

    HealthTech guidance
    Published
    27 January 2021
    View recommendations

    Sections for HTG564

  5. Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (HTG391)

    Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. This involves implanting a stimulator device into the upper buttock to restore the ability to empty the bladder voluntarily.

    HealthTech guidance
    Published
    25 November 2015
    View recommendations

    Sections for HTG391

  6. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued Reference number: GID-TAG221

    Technology appraisal guidance
    Discontinued

  7. What is the clinical and cost effectiveness of cannabis-based medicinal products other than THC: CBD spray for children, young people and adults with spasticity? In particular, what is the impact of spasticity on improvements in quality of life?

    (licensed product in UK: Sativex) for treating spasticity in people with multiple sclerosis. There were reductions in some measures of...

    Research recommendation
    Published
    10 February 2020

  8. Past appeals and decisions

    Past technology appraisal appeals and decisions

  9. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued Reference number: GID-TA10306

    Technology appraisal guidance
    Discontinued

  10. Tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions) (HTG191)

    Evidence-based recommendations on tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions). This involves cutting the horizontal muscles of the eye (which move the eye from side to side) and reattaching them at the same place.

    HealthTech guidance
    Published
    27 May 2009
    View recommendations

    Sections for HTG191

  11. Transabdominal artificial bowel sphincter implantation for faecal incontinence (HTG177)

    Evidence-based recommendations on transabdominal artifical bowel sphincter implantation for faecal incontinence. This involves inserting an artificial sphincter through a cut in the abdomen.

    HealthTech guidance
    Published
    26 November 2008
    View recommendations

    Sections for HTG177

  12. What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with primary cerebral conditions with lower urinary tract dysfunction?

    dysfunction, as well as those with spinal cord injury, spina bifida and multiple sclerosis. Reports of its use in other conditions are...

    Research recommendation
    Published
    9 June 2015

  13. Management strategies to reduce the risk of symptomatic urinary tract infections:- In people with neurogenic lower urinary tract dysfunction, which management strategies (including the use of prophylactic antibiotics and various invasive and non-invasive techniques to aid bladder drainage) reduce the risk of symptomatic urinary tract infections?

    renal function. In the population with neurological diseases such as multiple sclerosis, Parkinson's disease and dementia, the rise in...

    Research recommendation
    Published
    9 June 2015

  14. Insertion of a magnetic bead band for faecal incontinence (HTG336)

    Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.

    HealthTech guidance
    Published
    27 March 2014
    View recommendations

    Sections for HTG336

  15. Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)

    Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.

    Technology appraisal guidance
    Published
    4 June 2025

    Sections for TA1069